Oxford Events, the new replacement for OxTalks, will launch on 16th March. From now until the launch of Oxford Events, new events cannot be published or edited on OxTalks while all existing records are migrated to the new platform. The existing OxTalks site will remain available to view during this period.
From 16th, Oxford Events will launch on a new website: events.ox.ac.uk, and event submissions will resume. You will need a Halo login to submit events. Full details are available on the Staff Gateway.
Oncolytic adenoviruses replicate and amplify themselves within tumour cells, mediating targeted cytotoxicity as well as allowing tumour-selective expression of encoded biologics such as cytokines or checkpoint inhibitor antibodies, for secretion into the tumour microenvironment. We have developed adenoviruses suitable for i.v. delivery to disseminated disease in humans, and are now ‘arming’ them to express bispecific T cell engagers (BiTEs) capable of activating endogenous T cells to attack endogenous tumour cells. This new generation of viruses can combine targeted cytotoxicity, local reversal of immune suppression and intratumoural activation of T cells to give a combined therapeutic effect that can be rapidly translated into the clinic.
